AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04446182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: All eligible patients will begin study therapy with approximately a week lead-in of itacitinib monotherapy at scheduled dose. Itacitinib will be taken daily at scheduled dose for a total of six cycles. Itacitinib may be tapered as deemed appropriate by the treating investigator. Patients will remain on study therapy as long as treatment discontinuation criteria are not met. Patients with Partial Response (PR) or better may continue itacitinib for up to 1 year.
Study NCT04446182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis (ECP)
Description: ECP will begin after itacitinib lead in period. At the end of 8 weeks of combination therapy, patients will start a standard ECP taper schedule. Patients achieving PR or better after 6 cycles of itacitinib may continue treatment with itacitinib for up to 1 year. Thereafter, itacitinib may be tapered at the treating investigator's discretion.
Study NCT04629209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
Study NCT05338749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Gamified cognitive training intervention to improve mental speed and attention.
Study NCT05602558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB001
Description: The antigen consists of receptor-binding domain (RBD) from wild-type SARS-CoV-2 displaying on virus-like particle (VLP) vector, adjuvanted with aluminium hydroxide.
Study NCT05318027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChatBot
Description: The automated chatbot will check in with the patient on two pre-specified days between scheduled outpatient visits. The chatbot will follow pre-specified symptom algorithms and classify symptoms as requiring high, intermediate and low risk follow ups. High risk symptoms will trigger a same day nursing/physician visit or telemedicine call/video. Intermediate risk symptoms will trigger a nursing triage visit or telemedicine call/video on the next day or treatment day. Low risk symptoms will notify the treating physician to address the symptoms at the next scheduled on treatment visit (OTV). If adjustments are needed in the chat bot triage algorithms, they will be updated in real time to decrease risk for adverse patient events.
Study NCT06195137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: caffeine supplementation
Study NCT06195137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Lipoic Acid
Description: 600-800 mg ALA
Study NCT05074368 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1-nCov-19 (Astra-Zeneca)
Description: vaccine inoculation and mixed inoculation
Study NCT05074368 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
Description: vaccine inoculation and mixed inoculation
Study NCT05765864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Enrollment questionnaire, General questionnaire1, General questionnaire2, General questionnaire3
Description: The questionnaires will cover general and demographic data, information on previous treatments, medication received, mental disorder at discharge (ICD), psychosocial situations (ICD), physical illnesses (ICD), COVID status (vaccinated, recovered, tested), use of psychoactive substances, history of self-harm, suicide attempts, school performance, experience with peers, sexual orientation and identity, residence, family composition, family history of mental disorders, self-harm and suicide attempts.
Study NCT05765864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Columbia Suicide Severity Rating Scale (CSSRS)
Description: The questionnaire is scientifically supported, has the most evidence of utility and efficacy, and is internationally accepted. It has been translated into more than 100 different languages, including Slovene. It is easy to use, suitable for all age groups and adapted for successful use outside the hospital setting, for example in schools, colleges, police, military and elsewhere. It contains 2 screening questions on suicidality and 4 more specific questions, 6 items in total.~Posner K, Brown GK, Stanley B, et al. Am J Psychiatry 2011;168:1266-77.
Study NCT05765864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Brief Non-Suicidal Self-Injury Assessment Tool (B-NSSI-AT)
Description: used for research purposes to assess the core characteristics of NSSI (form, frequency, function) as well as the secondary characteristics of NSSI (habituation, context of NSSI, perceived impact on life and treatment).~Whitlock J, Exner-Cortens D, Purington A. Psychol Assess 2014;26:935-46.
Study NCT05765864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Experiences in Close Relationships-Relationship Structures (ECR-RS)
Description: Assesses the pattern of attachment to attachment figures (friend, romantic partner, mother, father) in adults and adolescents. The questionnaire has been officially translated into Slovene and used with several samples of Slovene adults and adolescents.~Fraley RC, Waller NG, Brennan KA. J Pers Soc Psychol 2000;78:350-65.
Study NCT05765864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Trauma Symptom Checklist for Children (TSCC)
Description: The questionnaire helps to assess children's/adolescents' experiences of various traumatic experiences, such as physical or sexual violence, peer violence, loss, witnessing violent acts, natural disasters, etc. The questionnaire consists of 6 clinical scales (Anxiety, Depression, Anger, Post-traumatic Stress Symptom, Dissociativeness (two subscales), Sexual Concerns) and 2 validity scales. 6 clinical scales (Anxiety, Depressiveness, Anger, Post-traumatic Stress Symptom, Dissociativeness (two subscales), and 2 validity scales) are included.~https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikotravmatiziranostiotrokinmladostnik. aspx
Study NCT05765864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Personality Assessment Inventory-Adolescent (PAI-A)
Description: An objective-type self-assessment questionnaire for assessing personality in adolescents. It has 264 items to be answered on a 4-point scale. 22 independent scales are obtained (Inconsistency, Rarity, Negative impression, Positive impression, Physical complaints, Anxiety, Anxiety-related disorders, Depressiveness, Mania, Paranoid, Schizophrenia, Borderline traits, Antisocial traits, Alcohol problems, Drug problems, Aggressiveness, Suicidal ideation, Stress, Lack of support, Refusal to deal, Dominance, Warmth).~https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikzaocenoosebnosti-oblikazamladostnike-PAI-A.aspx
Study NCT05602558 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aluminium hydroxide adjuvant
Study NCT05324800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcuma Longa Extract Mixture
Description: 2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
Study NCT05324800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: 2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
Study NCT04952376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS delivery of information
Description: Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. Links to information or phone for scheduling will be provided. Messages mimic the clinic's usual practice of information delivery to patients
Study NCT04952376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized text message delivery of information
Description: Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. The SMS message is personalized as a recommendation from the primary care clinician
Study NCT04952376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive or 2-way SMS delivery of information
Description: This intervention is same as in the Arm 2 using personalized messaging from the PCP. In addition, patients are given interactive or 2-way SMS options to obtain additional information about COVID vaccine and answers to frequently asked questions.
Study NCT06092684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT-KTM-I
Description: The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
Study NCT06092684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketanest®S
Description: The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
Study NCT04686773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: AZD1222 (0.5 ml per dose) contains:~Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles per dose.~Solution for intramuscular injection, supplied in vials (5 mL, up to 10 doses per vial) in a carton box.
Study NCT04686773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd26-S
Description: Component I (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose.~Solution for intramuscular injection, supplied in vials (3 mL, 5 doses per vial) in a carton box
Study NCT05246852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: healthy lifestyle education
Description: A total of 6 sessions on physical activity, nutrition, substance abuse, sexual life, check-up, accidents and injuries will be organized for the adolescents in the intervention group. The sessions will be organized every other week. Each session will be conducted in three stages. First Stage: The researcher will provide training on the subject of the session for nearly 15 minutes. Second Stage: The researcher will show animation film (nearly 3 to 5 minutes) developed by him/her related to the session. Third Stage: Groups of six will be created for the Philips 66 technique application and a spokesman will be chosen. Each group will have an online meeting and discuss the session subject in six minutes under the administration of the researcher. The spokesman of each group will present the discussion outcome in the big group meeting at the end of the discussion. The researcher will summarize the subject after the presentation of each spokesman and terminate the session.
Study NCT05460195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab combined with anlotinib
Description: Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab combined with anlotinib therapy repeats every 3 weeks until one year after surgery.
Study NCT05460195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab monotherapy
Description: Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab monotherapy repeats every 3 weeks until one year after surgery.
Study NCT05137028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise
Description: Otago exercise protocol~Strengthening exercise:~Resistance exercise for knee flexors, knee extensors, hip abductor, ankle dorsiflexors, ankle planterflexors~Balance exercise:~knee bending, backward walking, walking and turning around, sideway walking, tendem stance, tendem walking, one leg stand, heel walking, toe walking, heel to toe walking, sit to stand, stair walking
Study NCT04762706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRUTCH Pathway
Description: Patients will be offered referral to a behavioral medicine specialist in the novel Combined Rehabilitation Using Team Centered Help (CRUTCH) Pathway. Once enrolled, these patients will meet virtually with a psychiatrist. The psychiatrist will complete a 30-minute intake visit where he will review the patient's DT scoring, discuss contributing factors to current distress level, and assess for psychiatric comorbidities. Following this assessment, psychotherapy, psychotropic medication, and referral for social work/financial services will be offered to the patient as indicated. If more frequent behavioral health follow-up is clinically indicated, it will be provided to the patients.
Study NCT04909866 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TACE+Lenvatininb+Camrelizumab
Description: Patients included in the trial were treated with TACE, lenvatinib combined with Camrelizumab.
Study NCT05598762 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Tape strips
Description: Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.
Study NCT06060912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left Atrial Appendage Occlusion
Description: Left Atrial Appendage Occlusion will be performed according to current international standards by experienced operators under TOE and angiographic guidance. Either a LAmbre occlusion device (group A) or an AMPLATZER Amulet occlusion device (group B) will be implanted depending on treatment allocation.
Study NCT06060912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Occlusion
Description: Left Atrial Appendage Occlusion will be performed according to current international standards by experienced operators under TOE and angiographic guidance. Either a LAmbre occlusion device (group A) or an AMPLATZER Amulet occlusion device (group B) will be implanted depending on treatment allocation.
Study NCT06459427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Stereotactic Brainstem Hematoma Puncture
Description: Positioning and surgical procedures are carried out based on the use of robotic navigation equipment. Precise preoperative design is conducted using preoperative imaging data to create a preoperative three-dimensional visualization model. During surgery, robot-assisted stereotactic puncture is performed. First day, urokinase may be used as needed to assist in dissolving residual hematoma and adjusting the depth of the drainage tube. For every 10 mL of hematoma, 1 mL of 10,000 IU urokinase in 0.9% sodium chloride solution is injected, followed by flushing with 2 mL of 0.9% sodium chloride solution through the tube after closing it for 2 hours, and then reopening it. Urokinase injections into the drainage tube are used 1-2 times daily to facilitate hematoma drainage. Third day, if the residual hematoma volume is \<3 mL or if the drainage tube has been in place for >5 days, the drainage tube is removed.
Study NCT06459427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conservative non-surgical treatment
Description: Oxygen therapy, intensive care, maintaining stable blood pressure (targeting 140/90 mmHg), sedation, intracranial pressure control, arousal promotion, gastric protection, maintaining homeostasis, infection control, neurological nutrition, brain function improvement, nutritional support, general condition improvement, and other treatments are provided. For comatose patients, ensuring airway patency, administering nebulized expectorants, preventing respiratory depression, improving respiratory function, and performing tracheostomy if necessary are part of the care plan. Close monitoring of patients' conditions and proactive symptomatic treatment are prioritized. Regular follow-up cranial CT scans are scheduled to monitor intracranial conditions. Ventricular puncture drainage is considered if there is concomitant intraventricular hemorrhage or obstructive hydrocephalus (with patient consent).
Study NCT06459427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conservative non-surgical treatment
Description: Oxygen therapy, intensive care, maintaining stable blood pressure (targeting 140/90 mmHg), sedation, intracranial pressure control, arousal promotion, gastric protection, maintaining homeostasis, infection control, neurological nutrition, brain function improvement, nutritional support, general condition improvement, and other treatments are provided. For comatose patients, ensuring airway patency, administering nebulized expectorants, preventing respiratory depression, improving respiratory function, and performing tracheostomy if necessary are part of the care plan. Close monitoring of patients' conditions and proactive symptomatic treatment are prioritized. Regular follow-up cranial CT scans are scheduled to monitor intracranial conditions. Ventricular puncture drainage is considered if there is concomitant intraventricular hemorrhage or obstructive hydrocephalus (with patient consent).
Study NCT06316401 — intervention group
Intervention type: PROCEDURE
Intervention: ESD of large LSTs under SA
Description: endoscopic submucosal dissection of large colorectal lesions under spinal anesthesia
Study NCT04704791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PA-LAA shunt
Description: At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
Study NCT04846322 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PD4ED 3-step intervention (ED assessment, outpatient assessment, Brain health plan)
Description: 1. ED assessment for suspected dementia.~2. positive ED patients referred for outpatient clinic cognitive impairment assessment.~3. positive clinic patients referred to primary care with brain health patient plan.
Study NCT06303102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual PT/ Conventional PT Treatment + Segmental and Pursed Lip Breathing Exercise
Description: 20 patients will receive conventional physical therapy treatment (hot pack, electrical stimulation, myofascial release, ROM and strengthening exercises) along with segmental and pursed lip breathing exercises.
Study NCT06303102 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Manual PT/Conventional PT Treatment
Description: 20 patients will receive conventional physical therapy treatment (hot pack, electrical stimulation, myofascial release, ROM and strengthening exercises).
Study NCT05765864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Inventory Of Statements About Self-Injury; ISAS
Description: A self-assessment questionnaire used for research purposes to assess the basic characteristics of NSSI (form, frequency, function, time to event). It also assesses the desire to stop. The questionnaire has been previously translated into Slovene and used in a population of adolescents with self-injurious behaviour.~Glenn CR, Klonsky ED. One-year test-retest reliability of the Inventory of Statements about Self-Injury (ISAS). Assessment. 2011 Sep;18(3):375-8. doi: 10.1177/1073191111411669.
Study NCT05765864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Level of Personality Functioning Scale-Brief Form 2.0; LPFSBF 2.0
Description: A short, user-friendly instrument that gives a quick impression of the expression of personality pathology. It consists of 12 items grouped into two higher-order domains: self-functioning and interpersonal functioning. Participants are asked to rate the 12 items on a four-point Likert scale ranging from 1 (completely false) to 4 (completely true). A total score (sum of all items), a self-functioning score (sum of items 1-6) and an interpersonal functioning score (sum of items 7-12) can be calculated. Satisfactory internal consistency and promising construct validity have been demonstrated. Sensitivity to change after three months of treatment was high.~Weekers LC, Hutsebaut J, Kamphuis JH. The Level of Personality Functioning Scale-Brief Form 2.0: Update of a brief instrument for assessing level of personality functioning. Personal Ment Health 2019;13:3-14.
Study NCT05765864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Borderline Personality Features Scale, BPFSC-11
Description: The BPFS-C-11 includes BPD indicators such as affective instability, identity problems and negative attitudes. Responses to the items are on a 5-point Likert scale ranging from 'not at all true' to 'always true'. Studies have shown construct validity of interpretations of BPFS-C-11 scores through positive associations with other measures of BPD and positive associations with measures of BPD correlates, including emotional dysregulation. In a recent sample, the Cronbach's α over 4 years of follow-up was 0.86, 0.85, 0.86 and 0.90, respectively. The scale has been officially translated into Slovenian and will be used with the permission of the authors. It is intended for use by children and adolescents aged 9-11 years and consists of 11 items.~Sharp, C., Steinberg, L., Temple, J., Newlin, E. An 11-Item Measure to Assess Borderline Traits in Adolescents: Refinement of the BPFSC Using IRT . Personality Disorders: Theory, Research, and Treatment 2014;5(1):70-78.
Study NCT05765864 — intervention group
Intervention type: OTHER
Intervention: Dynamic Appraisal of Situational Aggression-Youth Version (DASA-YV)
Description: It's a professional assessment tool which provides a daily assessment of the risk of heteroaggression. The evaluation is efficient and takes less than five minutes. The nurse in charge of each patient completes the DASA-YV once a day.~Dutch SG, Patil N. Validating a Measurement Tool to Predict Aggressive Behavior in Hospitalized Youth. J Am Psychiatr Nurses Assoc 2019;25:396-404.
Study NCT05765864 — intervention group
Intervention type: OTHER
Intervention: Adolescent Self-Harm Risk Scale; ASHRS
Description: It's a professional assessment tool which provides a daily assessment of the risk of heteroaggression. This is the scale we developed for the present study. It will be used to assess and predict the short-term risk of self-harm behaviour during hospitalisation (assessment at admission) and the long-term risk after discharge (assessment at discharge).